¡¡
¡¡
¡¡
HOME > ÇÐȸ°£Ç๰ > ¿ë¾î»çÀü
Á¦¸ñ Drug resistance in Mycobacterium leprae
ÀúÀÚ Yoshiko Kashiwabara Ph.D. ¼Ò¼Ó Department of Microbiology, Leprosy Research Center . National Institute of Infectious Diseases Tokyo. Japan
³âµµ 1999 ±Ç 32
È£ 2 ¹øÈ£ 1
½ÃÀÛÆäÀÌÁö 1 ³¡ÆäÀÌÁö 4
÷ºÎ
¿ä¾à Leprosy is a chronic infectious disease caused by Mycobacterium leprae and is still a major health
problem in developing countries of Asia , Latin America and Africa , Global efforts to control by intensive chemotherapy have lead to a significant decrease in the number of patients of leprosy.
WHO introduced multidrug therapy (MDT) in 1981
and have settled the goal of the elimination of leprosy by 2000.
Multidrug therapy (MDT), which has been used worldwide , decreased the number of registered patients of leprosy dramatically.
However , the number of the newly detected patients in every year has been kept more than 0.5 million in these 15 years and the emergence of the drug-resistant M. leprae had been reported .
However , it is difficult to conduct the drug-susceptibility tests in short periods using clinical specimens , because M. feprae is not cultivable in artificial media .
Recent advances in mycobacterial genetics have made it possible to clarify molecular mechanisms
of drug actions and resistance.
We recently developed the rapid detection methods of drug resistance in M. leprae by analyzing the
sequences of the four genes involved in drug-resistance .
I will present recent results of our study on drug-resistance in M. leprae.
³»¿ë
 
¡¡
¡¡
¡¡